%PDF-1.4
%
49 0 obj
<>
endobj
46 0 obj
<>
endobj
152 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-07-09T09:15:18Z
2024-03-28T19:27:35-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T19:27:35-07:00
application/pdf
Heather
2003-595.aug
uuid:36e784d4-1dd2-11b2-0a00-cd08275d6100
uuid:36e784d7-1dd2-11b2-0a00-aa0000000000
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
172 0 obj
[177 0 R]
endobj
173 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:8)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1550)Tj
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 2.25 84.8494 Td
[(infection. N Engl J Med 2002;345:1)37 (175-86.)]TJ
-1.8 -1.25 Td
[(10.)-550 (The EuroGast Study Group. Epidemiology of, and risk factors for)40 (,)]TJ
/T1_1 1 Tf
1.8 -1.25 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
8.1582 0 Td
(infection among 3194 asymptomatic subjects in)Tj
0 Tc -8.1582 -1.25 Td
(17 populations. Gut 1993;34:1672-6.)Tj
-0.00011 Tc -1.7631 -1.25 Td
[(1)37 (1.)-550 (Sitas F)80 (, Forman D, )37 (Y)100 (arnell JW)92 (, et al. )]TJ
/T1_1 1 Tf
16.7615 0 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
0 Tw 8.1582 0 Td
(infection)Tj
0.02499 Tw -23.1565 -1.25 Td
[(rates in relation to age and social class in a population of )18 (W)80 (elsh)]TJ
0 -1.25 TD
(men. Gut 1991;32:25-8.)Tj
-1.8 -1.25 Td
[(12.)-550 (W)80 (ebb PM, Knight )18 (T)74 (, Greaves S, et al. Relation between infection)]TJ
0 Tw 1.8 -1.25 Td
(with )Tj
/T1_1 1 Tf
0.02499 Tw 2.0526 0 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
8.1582 0 Td
(and living conditions in childhood:)Tj
-10.2108 -1.25 Td
(evidence for person to person transmission in early life. BMJ 1994;)Tj
0 Tc 0 Tw T*
(308:750-3.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(13.)-550 (Marshall B. )]TJ
/T1_1 1 Tf
[-0.5 (Helicobacter pylori)]TJ
/T1_2 1 Tf
[-0.3 (: 20 years on. Clin Med )]TJ
0 Tc 0 Tw 1.8 -1.25 Td
(2002;2:147-52.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(14.)-550 (Kuipers EJ, Pena )55 (AS, van Kamp G, et al. Seroconversion for)]TJ
/T1_1 1 Tf
1.8 -1.25 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
[-0.2 (. Lancet 1993;342:328-31.)]TJ
-1.8 -1.25 Td
[(15.)-550 (Kosunen )18 (TU, Seppala K, Sarna S, Sipponen P)111 (. Diagnostic value of)]TJ
1.8 -1.25 Td
(decreasing IgG, IgA, and IgM antibody titres after eradication of)Tj
/T1_1 1 Tf
T*
(Helicobacter pylori)Tj
/T1_2 1 Tf
[-0.2 (. Lancet 1992;339:893-5.)]TJ
-1.8 -1.25 Td
[(16.)-550 (Halme L, Rautelin H, Leidenius M, Kosunen )18 (TU. Inverse )]TJ
1.8 -1.25 Td
(correlation between )Tj
/T1_1 1 Tf
(Helicobacter pylori)Tj
/T1_2 1 Tf
16.3701 0 Td
(infection and inflammatory)Tj
-16.37 -1.25 Td
(bowel disease. J Clin Pathol 1996;49:65-7.)Tj
-1.8 -1.25 Td
[(17.)-550 (Parente F)80 (, Molteni P)111 (, Bollani S, et al. Prevalence of )]TJ
/T1_1 1 Tf
0 Tw 22.7976 0 Td
(Helicobacter)Tj
-20.9976 -1.25 Td
(pylori)Tj
/T1_2 1 Tf
0.02499 Tw 2.6634 0 Td
(infection and related upper gastrointestinal lesions in patients)Tj
-2.6634 -1.25 Td
[(with inflammatory bowel diseases. )55 (A)-220 (cross-sectional study with)]TJ
T*
[(matching. Scand J Gastroenterol 1997;32:1)37 (140-6.)]TJ
-1.8 -1.25 Td
[(18.)-550 (Pearce CB, Duncan HD, )18 (T)35 (immis L, Green JR. )55 (Assessment of the)]TJ
1.8 -1.25 Td
(prevalence of infection with )Tj
/T1_1 1 Tf
[-0.3 (Helicobacter pylori)]TJ
/T1_2 1 Tf
19.7523 0 Td
(in patients with)Tj
-19.7523 -1.25 Td
(inflammatory bowel disease. Eur J Gastroenterol Hepatol)Tj
0 Tc 0 Tw T*
(2000;12:439-43.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(19.)-550 (V)111 (are PO, Heikius B, Silvennoinen JA, et al. Seroprevalence of)]TJ
/T1_1 1 Tf
1.8 -1.25 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
8.1582 0 Td
(infection in inflammatory bowel disease: is)Tj
/T1_1 1 Tf
-8.1582 -1.25 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
8.1582 0 Td
(infection a protective factor? Scand )Tj
24.8418 38.75 Td
(J Gastroenterol 2001;36:1295-300.)Tj
-1.8 -1.25 Td
[(20.)-550 (T)70 (an EM, Cohen )55 (AS, Fries JF)80 (, et al. )18 (The 1982 revised criteria for the)]TJ
1.8 -1.25 Td
[(classification of systemic lupus erythematosus. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(21.)-550 (Hochber)18 (g MC. Updating the )55 (American College of Rheumatology)]TJ
1.8 -1.25 Td
(revised criteria for the classification of systemic lupus )Tj
T*
[(erythematosus. )55 (Arthritis Rheum 1997;40:1725.)]TJ
-1.8 -1.25 Td
[(22.)-550 (Karttunen )18 (TJ, Niemela S, Kerola )18 (T)74 (. Blood leukocyte dif)18 (ferential in)]TJ
/T1_1 1 Tf
1.8 -1.25 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
8.1582 0 Td
(infection. Dig Dis Sci 1996;41:1332-6.)Tj
-9.9582 -1.25 Td
[(23.)-550 (Mendall M, Patel P)111 (, Ballam L, Strachan D, Northfield )18 (T)74 (. C reactive)]TJ
1.8 -1.25 Td
(protein and its relation to cardiovascular risk factors: a population)Tj
T*
[(based cross sectional study)65 (. BMJ 1996;312:1061-5.)]TJ
-1.8 -1.25 Td
[(24.)-550 (Mendall MA, Patel P)111 (, )55 (Asante M, et al. Relation of serum cytokine)]TJ
1.8 -1.25 Td
(concentrations to cardiovascular risk factors and coronary heart)Tj
T*
(disease. Heart 1997;78:273-7.)Tj
-1.8 -1.25 Td
[(25.)-550 (Leontiadis GI, Sharma )18 (VK, Howden CW)92 (. Non-gastrointestinal tract)]TJ
1.8 -1.25 Td
(associations of )Tj
/T1_1 1 Tf
[-0.3 (Helicobacter pylori)]TJ
/T1_2 1 Tf
14.3728 0 Td
[(infection. )55 (Arch Intern Med)]TJ
0 Tc 0 Tw -14.3727 -1.25 Td
(1999;159:925-40.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(26.)-550 (Showji )37 (Y)129 (, Nozawa R, Sato K, Suzuki H. Seroprevalence of)]TJ
/T1_1 1 Tf
1.8 -1.25 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
8.1582 0 Td
(in patients with connective tissue diseases.)Tj
-8.1582 -1.25 Td
(Microbiol Immunol 1996;40:499-503.)Tj
-1.8 -1.25 Td
[(27.)-550 (Thye )18 (T)74 (, Burchard GD, Nilius M, Muller)20 (-Myhsok B, Horstmann RD.)]TJ
1.8 -1.25 Td
(Genomewide linkage analysis identifies polymorphism in the human)Tj
T*
[(interferon-gamma receptor af)18 (fecting )]TJ
/T1_1 1 Tf
14.8526 0 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
0 Tw 8.1582 0 Td
(infection.)Tj
0.02499 Tw -23.0107 -1.25 Td
(Am J Hum Genet 2003;72:448-53.)Tj
-1.8 -1.25 Td
[(28.)-550 (El-Omar EM, Carrington M, Chow )18 (WH, et al. Interleukin-1 )]TJ
1.8 -1.25 Td
[(polymorphisms associated with increased risk of gastric cancer)55 (.)]TJ
T*
(Nature 2000;404:398-402.)Tj
-1.8 -1.25 Td
[(29.)-550 (Lundgren )55 (A, Suri-Payer E, Enarsson K, Svennerholm )55 (AM, Lundin)]TJ
0 Tc 0 Tw 1.8 -1.25 Td
(BS. )Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 1.7479 0 Td
(Helicobacter pylori)Tj
/T1_2 1 Tf
[-0.2 (-specific CD4+ CD25 high regulatory )18 (T)]TJ
-1.7479 -1.25 Td
[(cells suppress memory )18 (T)92 (-cell responses to )]TJ
/T1_1 1 Tf
17.2003 0 Td
(H. pylori)Tj
/T1_2 1 Tf
3.9104 0 Td
(in infected )Tj
-21.1106 -1.25 Td
(individuals. Infect Immun 2003;71:1755-62.)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
109.22 59.08 396.48 -10.83 re
f*
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
29 0 obj
<>stream
8;Z\5Mf&VO#ikr7OPe`u`5Z%gX`cY&'>CVL#:3adEA&"i%;+ur%/+V?08p];"R9FO
XZ_sorHq++=-#'fn"pl,5KuJ8mq9lHFe]YU8:=^t"#-RO-'q46k50K]=?,A\_)VUB
d,i+]Bj4VcC:DRS4&"NS'$!iCShWp7,?5Ko-:p9`Y,_`=CrR>c9JkTmah%,"9(mD_^!UhVaeZF:<,
MLEHh[G3@)*utnW`VpmN!\0EZTSl.G1rjc;jd!$ciC-279TAl$kR\[8%:-o1Q\RVH
GGG3Tj)Zn*n("L:V^LK0DD33=2.bAFZfucRc:pAEFQ-D=&?oCqdsK03&B)bMPsnf^
ip"FW6CuS_]T86;c3^TkPR3,lE*E"ZbC_SbbM:V8nNZVF+OA8e3YD[I[cJg;rK0R8
A5i>h0tA&f>/?@!:?RFKpDPWS)WZSW5>qqJG6]W8dc\>mI4Z3AKgMJ0-km#B_M>q`
a"9Re&T=`<4`A6-5F^9>`n(4NNaU6~>
endstream
endobj
33 0 obj
[/Indexed/DeviceRGB 255 32 0 R]
endobj
32 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
104 0 obj
<>
endobj
52 0 obj
<>
endobj
59 0 obj
<>
endobj
125 0 obj
<>
endobj
158 0 obj
<>
endobj
58 0 obj
<>
endobj
84 0 obj
<>stream
H|RiTWVBFH((ThdnADh7"2"*ȪDqaP65ʈ8ɨAA3:-ɴNΜ5s;1Cq*?/1 rCK8Kogap#Ȑ#7%s;r?وu&ȴܒ2Hq**U3:Iba'qruYC^1J<"rɦTMb5\#WW?rh$2IZ)O$(OBK